AMAR - Amarillo Biosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
-0.0181 (-6.14%)
At close: 9:30AM EST
Stock chart is not supported by your current browser
Previous Close0.2950
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2769 - 0.2769
52 Week Range0.1220 - 0.5400
Avg. Volume4,964
Market Cap11.136M
Beta (5Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)-0.0430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.90
  • GlobeNewswire

    Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement

    Amarillo, TX, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Xiamen Weiyang”), setting forth the proposed terms for a cooperative development and licensing venture in China.  The consummation of the proposed transaction is contingent on a mutually agreeable definitive agreement. Dr. Stephen T. Chen, ABI’s CEO, stated, “We are pleased to announce this proposed venture with Xiamen Weiyang.